Showing 1 - 10 of 32
Persistent link: https://www.econbiz.de/10001780824
Persistent link: https://www.econbiz.de/10001180834
Persistent link: https://www.econbiz.de/10001169197
Medical care at the end of life, estimated to contribute up to a quarter of US health care spending, often encounters skepticism from payers and policy makers who question its high cost and often minimal health benefits. It seems generally agreed upon that medical resources are being wasted on...
Persistent link: https://www.econbiz.de/10014198525
Medical care at the end of life, estimated to contribute up to a quarter of US health care spending, often encounters skepticism from payers and policy makers who question its high cost and often minimal health benefits. However, though many observers have claimed that such spending is often...
Persistent link: https://www.econbiz.de/10013148867
Public technology assessments in general and Comparative Effectiveness Research (CER) in particular have been justified by offsetting benefits of improving patient health and reducing health care spending. However, little conceptual and empirical understanding exists concerning the quantitative...
Persistent link: https://www.econbiz.de/10013149296
Public subsidization of technology assessments in general, and Comparative Effectiveness Research (CER) in particular, has received considerable attention as a tool to simultaneously improve patient health and lower the cost of health care. However, little conceptual and empirical understanding...
Persistent link: https://www.econbiz.de/10013092707
"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. Public subsidization of technology assessments in general, and Comparative Effectiveness Research (CER) in particular, has received...
Persistent link: https://www.econbiz.de/10003925198
Persistent link: https://www.econbiz.de/10003926717
Persistent link: https://www.econbiz.de/10009303017